Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001193125-25-282663·Anson Funds Management LP
Schedule 13G ownership disclosure
ONCOLYTICS BIOTECH INC
Common Stock, no par value · CUSIP: 682310875
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Anson Funds Management LP
Shares: 7,649,050 · Class: 7%
- Anson Management GP LLC
Shares: 7,649,050 · Class: 7%
- Tony Moore
Shares: 7,649,050 · Class: 7%
- Anson Advisors Inc.
Shares: 7,649,050 · Class: 7%
- Amin Nathoo
Shares: 7,649,050 · Class: 7%
- Moez Kassam
Shares: 7,649,050 · Class: 7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-282663
- Form type
- SCHEDULE 13G/A
- Filer
- Anson Funds Management LP
- CIK
- CIK 1491072
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership